Patients with NYHA II symptoms had a mean daily total step count of 5729 steps, while those with NYHA III symptoms had a mean of 3541 steps, indicating significant differences in physical activity levels (P=.04).
Observational (n=50)
No
Does free-living step count monitoring improve the objective assessment of functional classification in adults with stable chronic heart failure?
Free-living step counts measured by a commercial wearable device can objectively differentiate between NYHA class II and III in patients with HFrEF, offering a potential objective measure of functional capacity.
Absolute Event Rate: 5729% vs 3541%
p-value: p=.04
Patients with NYHA II and III symptoms differed significantly by various aggregate measures of free-living step count including the (1) mean and (2) maximum daily total step count as well as by the (3) mean of daily mean step count and by the (4) mean and (5) maximum of the daily per minute step count maximum. These findings affirm that the degree of exercise intolerance of NYHA II and III patients as a group is quantifiable in a replicable manner. This is a novel and promising finding that suggests the existence of a possible, completely objective measure of assessing HF functional class, something which would be a great boon in the continuing quest to improve patient outcomes for this burdensome and costly disease.
Baril et al. (Tue,) conducted a observational in Heart Failure with reduced ejection fraction (HFrEF) (n=50). Free-Living Step Count Monitoring with Fitbit was evaluated on Mean daily total step count (p=.04). Patients with NYHA II symptoms had a mean daily total step count of 5729 steps, while those with NYHA III symptoms had a mean of 3541 steps, indicating significant differences in physical activity levels (P=.04).